Plus, Jazz Pharmaceuticals has relied heavily on M&A activity to achieve its current position in the industry and the acquisition of Celator Pharmaceuticals shows that Jazz Pharmaceuticals is still serious about using M&A to continue to grow its revenues. As I pointed in the previous section, Erwinaze was developed to treat acute lymphoblastic leukemia. Vyxeos fits in well with Jazz Pharmaceuticals because the company already has experience with leukemia drugs. Although Jazz Pharmaceuticals' primary product is a narcolepsy drug, Vyxeos fits in perfectly with Jazz Pharmaceuticals' long-term strategy. In my opinion, Celator Pharmaceuticals was a fantastic acquisition for Jazz Pharmaceuticals. The product is expected to treat poor prognosis patients and the Phase 3 results produced fantastic results. The company's primary product is Vyxeos, which treats Acute Myleoid Leukemia. On May 31, 2016, Jazz Pharmaceuticals announced that they were acquiring Celator Pharmaceuticals in an all cash deal. However, I do think that the product still has room to grow, which I point out in future sections. until 2016, the drug was commercially in Europe in 2014.Īs I point in future sections, the company's heavy reliance on Xyrem is somewhat concerning. Even though the drug was not launched in the U.S. Also, the drug is the first FDA approved treatment for the rare and life threatening disease. The drug is used for the treatment of children and adults hepatic venocclusive disease. Although the drug is a fairly small portion of the company's current sales, Defitelio was only approved by the FDA in the U.S. Lastly, Defitelio was 5.4% of the company's net product sales. Erwinaze is used in patients who have had an allergic reaction to a different type of asparaginase treatment." According to the Erwinaze website, Erwinaze "is part of a chemotherapy program to treat patients who have acute lymphoblastic leukemia, a type of blood cancer that affects the white blood cells that help fight infection.
Secondly, Erwinaze accounts for 15.4% of the company's net product sales. is 12,550 and the company stated in its 2015 10-K that there are significantly more narcoleptic patients with cataplexy and/or who could benefit from treatment with Xyrem. Currently, the number of active Xyrem patients in the U.S. It is currently the only product approved by the FDA for the treatment of both excessive daytime sleepiness and cataplexy. by Jazz Pharmaceuticals and Valeant Pharmaceuticals ( VRX) in Canada. % of net product sales data from 2015 10-K, YoY Growth data from Q1 2016 Conference Call.Īs stated before, the company has three primary drugs, which account for 93.3% of the company's revenue.įirst off, the company's largest product is Xyrem, which was 72.5% of the company's net product sales. Comparatively, a similar investment in the NASDAQ Index ( QQQ) would have remained flat, but a similar investment in the NASDAQ Biotechnology Index ( IBB) would have roughly tripled. launch of Defitelio in 2016.įrom December 2010 to December 2015, a $100 investment would have increased six fold in just five years. The company has achieved many milestones and some of the many highlights of the company's history include a merger of Azur Pharma in 2012, the initiation of the JZP-110 Phase 3 clinical program and the U.S. The company was founded in 2003 and by 2005, Jazz Pharmaceuticals had acquired Orphan Medical and its product, Xyrem. Jazz Pharmaceuticals ( NASDAQ: JAZZ) is a biopharmaceutical company that is headquartered in Dublin, Ireland and the company has three primary drugs, which are Xyrem, Erwinaze, and Deifetelio.
0 kommentar(er)
